Early MRI-Derived Volumetric Thresholds Predict Response and Guide Personalization in HER2-Positive Breast Cancer: A Retrospective Study
Hao Yao, Xuyang Qian, Ran Zheng, Xingye Sheng, Jingjing Ding, Mingyu Wang, Xiaoming Zha, Shouju Wang, Jue Wang, Mohamad Adam Bujang · 2025
Read Early MRI-Derived Volumetric Thresholds Predict Response and Guide Personalization in HER2-Positive Breast Cancer: A Retrospective Study by Hao Yao, Xuyang Qian, Ran Zheng, Xingye Sheng, Jingjing Ding, Mingyu Wang, Xiaoming Zha, Shouju Wang, Jue Wang, Mohamad Adam Bujang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12730305.txt.
Description
A peer-reviewed research article from Europe PMC (2025). Background: Neoadjuvant systemic therapy (NST), whose primary purposes include response assessment and treatment individualization, is a key strategy in the treatment of HER2-positive breast cancer. This study investigated the predictive value of the magnetic resonance imaging (MRI)-derived tumor volume reduction rate (δV1) for the early identification of pathological complete response (pCR) during NST and established clinically applicable δV1 thresholds for patient stratification. Methods: HER2-positive breast cancer patients who received THP (taxane, trastuzumab, pertuzumab) followed by epirubicin/cyclophosphamide (EC) were enrolled.
Catalog record
| CREATOR | Hao Yao, Xuyang Qian, Ran Zheng, Xingye Sheng, Jingjing Ding, Mingyu Wang, Xiaoming Zha, Shouju Wang, Jue Wang, Mohamad Adam Bujang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |